Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Respiratory

Patent settlements saved Americans $25.5bn, GPhA says

This article was originally published in Scrip

Executive Summary

Patent settlements involving Pfizer's cholesterol-lowering drug Lipitor (atorvastatin), AstraZeneca's asthma medicine Pulmicort (budesonide) and Shire's attention deficit/hyperactivity disorder medication Adderall XR (amphetamine/dextroamphetamine mixed salts) and 30 other products saved US consumers and the nation's health care system $25.5 billion from 2005-2012, the Generic Pharmaceutical Association (GPhA) asserted on 9 July, basing its estimates on an analysis it paid IMS Institute for Healthcare Informatics to conduct.

Table

View full table

Topics

Related Companies

Tags:
Respiratory
Latest Headlines

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

China Biotech Podcast: AACR, BIOSECURE European Perspectives

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth

See All
UsernamePublicRestriction

Register

SC022016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By